New AstraZeneca Drug Offers Hope for Metastatic Breast Cancer Patients
- AstraZeneca’s Datopotamab Deruxtecan (Datroway) received FDA approval on January 16, 2025
- The drug treats previously treated metastatic HR+/HER2-negative breast cancer
- The TROP2-directed antibody drug conjugate offers a new treatment option earlier in the metastatic setting
- Approval was based on the successful TROPION-Breast01 Phase III trial results
- There is hope for the X annual U.S. patients diagnosed with this common form of breast cancer
A number of breast cancer experts have told SurvivorNet that this approval is significant.
Read More “The overall totality of the data showed that this is a superior option to standard chemotherapy, hence the FDA granted approval,” Dr. Aditya Bardia, an oncologist at UCLA Health Jonsson Comprehensive Cancer Center, tells SurvivorNet. “The approval of Datroway provides patients with HR+/HER2- breast cancer previously treated with endocrine-based therapy and traditional chemotherapy with the opportunity to be treated with a new TROP2-directed antibody drug conjugate earlier in the metastatic setting”, says Omer. For patients facing metastatic breast cancer, which means that cancer has spread into the body, Datroway represents a new option for patients in need. The drug’s journey to approval stemmed from the TROPION-Breast01 Phase III trial, which demonstrated its efficacy in patients who had progressed after standard treatments. Omer sees this as more than a regulatory win, it’s a potential shift in clinical practice. “Datroway is the latest addition to our portfolio of innovative cancer treatments and marks the fourth medicine from our oncology pipeline to receive approval in the U.S.,” she notes.
By targeting TROP2, a protein highly expressed in many breast cancers, Datroway introduces a precision approach that could redefine how oncologists manage this disease earlier in the metastatic phase.
For patients, Datroway’s approval offers hope for extended disease control.
Learn more about SurvivorNet's rigorous medical review process.
